Clemmensen Group

Read more
1 - 2 out of 2Page size: 10
  1. 2021
  2. Published

    GLP-1-mediated delivery of the PPAR\uD835\uDEFC/\uD835\uDEFE dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice

    Quarta, C., Stemmer, K., Novikoff, A., Yang, B., Klingelhuber, F., Harger, A., Bakhti, M., Bastidas-Ponce, A., Bauge, E., Clemmensen, Christoffer, Colldén, G., Cota, P., Drucker, D., García-Cáceres, C., Grandl, G., Hennuyer, N., Herzig, S., Hofmann, S., Kulaj, K., Lalloyer, F., Lickert, H., Maity, G., Perez-Tilve, D., Sanchez-Garrido, M. A., Zhang, Q., Staels, B., Krahmer, N., DiMarchi, R., Tschoep, M., Finan, B. & Müller, T., 30 Nov 2021

    Research output: Other contribution › Research

  3. 2020
  4. Published

    Compounds for the treatment of acute brain injury

    Klein, A. B., Leurs, U., Houlton, J., Clausen, Rasmus Prætorius, Frølund, Bente, Clarkson, A. & Wellendorph, Petrine, 2020, Patent No. CN111989094, 24 Nov 2020, Priority date 1 Feb 2019, Priority No. PCT/DK2019/050041

    Research output: Patent